ArticleBMC women's health2024
Approaches to prevention of gynecological malignancies.
Article in BMC women's health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- TCGA molecular subtypes in endometriosis-associated ovarian cancer: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- A meta-analysis of albumin, globulin, and albumin globulin ratios for predicting prognosis of cervical cancer.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025Pooled it
- Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Interim analysis of robot-assisted radical hysterectomy in Japan: a multicenter, prospective interventional single-arm clinical trial.BMC cancer · 2024Trial
- Comprehensive Analysis of Cuproptosis-Related Genes According to Cancer Stage and Their Prognostic Value in Cervical Cancer.International journal of molecular sciences · 2026Article
- Quantitative analysis of trends and inequalities in disease burden and care quality of gynecological cancers, 1990-2021.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- A Retrospective Study on the Clinicopathological Characteristics and Prognostic Analysis of Gynecologic Neuroendocrine Carcinoma.Cancer medicine · 2026Observational
- PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024.Human vaccines & immunotherapeutics · 2025Review
- Predictive value of models based on MRI radiomics and clinical indicators for lymphovascular space invasion in endometrial cancer.BMC cancer · 2025Article
- Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study.Oncology and therapy · 2025Article
- Article
- Significance of Gelsolin Superfamily Genes in Diagnosis, Prognosis and Immune Microenvironment Regulation for Endometrial Cancer.Cancer medicine · 2025Article
- Article
- Article
- Molecular subtype of ovarian clear cell carcinoma: an analysis of 80 Chinese patients using the TCGA molecular classification of endometrial cancer.BMC cancer · 2025Article
- RUNX1 promotes proliferation of cervical cancer through TGFB2-MAPK pathway.Scientific reports · 2025Article
- Prognostic analysis of single-agent olaparib or combination cediranib and olaparib for platinum sensitive recurrent ovarian cancer: overall survival outcomes from NRG-GY004.Gynecology and pelvic medicine · 2025Article
- Undetermined Ruptured Low-Grade Appendiceal Mucinous Neoplasm Following High-Energy Blunt Abdominal Trauma Requiring Emergency Laparotomy.Clinical case reports · 2025Article
- Identification and Clinical Validation of High HSP60 Expression Predicts Poor Prognosis in Patients with Ovarian Cancer.International journal of general medicine · 2025Article
- Multi-Omics Analysis Revealed That TAOK1 Can Be Used as a Prognostic Marker and Target in a Variety of Tumors, Especially in Cervical Cancer.OncoTargets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynecological malignancies represent one of the prevalent diseases in the female sex and prevention is essential to limit their incidence and mortality. Nowadays, not all malignancies benefit from adequate screening methods for this reason new biomarkers and methods are being developed to undertake timely and effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.